In vitro cytotoxic evaluation of some synthesized COX-2 inhibitor derivatives against a panel of human cancer cell lines

Research in Pharmaceutical Sciences

Volumn 8, Issue 4, 2013, Pages 299-304

  Sadeghi Aliabadi, H ^a   Aliasgharluo, M ^a   Fattahi, A ^b   Mirian, M ^b   Ghannadian, M ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

A 2780 s; Celecoxib; DNA fragmentation; HT 29; MDA MB 231; MTT assay

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; DNA FRAGMENT; DOXORUBICIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPHILICITY; OVARY CANCER; UTERINE CERVIX CANCER;

EID: 84873347272     PISSN: 17355362     EISSN: 17359414     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic acid oxygenation by COX-1 and COX-2, mechanisms of catalysis and inhibition. J Biol Chem. 1999;274:22903-22906.
2. Wright JM. The double edged sword of COX-2 selective NSAIDs. CMAJ. 2002;167:1131-1137.
3. Williams DA, Lemke TL, Roche VF, Zito SW. Foye's principles of medicinal chemistry, 6th ed. Lippincott Williams & Wilkins; 2007. p. 984-986.
4. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivity's for cyclo-oxygenase-1 rather than cyclo-oxygenase- 2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96:7563-7568. (Pubitemid 29299702)
5. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442. (Pubitemid 32747607)
6. Kismet K, Akay MT, Abbasoglu O, Ercan A. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect Prev. 2004;28:127-142. (Pubitemid 38448751)
7. Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst. 2003;95:1440-1452. (Pubitemid 37279329)
8. Shiff S, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal anti inflammatory drugs (NSAIDs). J Exp Med. 1999;190, 445-450. (Pubitemid 29395372)
9. Pyrko P, Kardosh A, Schönthal AH. Celecoxib transiently inhibits cellular protein synthesis. Biochem Pharmacol. 2008;75:395-404. (Pubitemid 350298464)
10. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 2002;531:278-284. (Pubitemid 35341208)
11. Zarghi A, Arfaei S and Ghodsi R. Design and synthesis of new 2, 4, 5-triarylimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors. Med Chem Res. 2011;21:1803-1810.
12. Sadeghi-aliabadi H, Ghasemi N, Kohi M. Cytotoxic effect of Convolvulus arvensis extracts on human cancerous cell line. Res Pharm Sci. 2008;3:31-34.
13. Sadeghi-Aliabadi H, Tabarzadi M, Zarghi A. Synthesis and cytotoxic evaluation of two novel anthraqhinone derivatives. Farmaco. 2004;59:645- 649. (Pubitemid 38950771)
14. Dounousi E, Koliousi E, Papagianni A, Ioannou K, Zikou X, Katopodis K, Kelesidis A, Tsakiris D, Siamopoulos KC. Mononuclear leukocyte apoptosis and inflammatory markers in patients with chronic kidney disease. Am J Nephrol. 2012;36:531-6.
15. Cheng H, Lundy Demello C, Li J, Sakya S, Ando K, Kawamura B, et al. Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitors. Bioorg Med Chem Lett. 2006;16:2076-2080. (Pubitemid 43351053)
16. Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med. 2006;355:950-952. (Pubitemid 44315987)
17. Raju U, Ariga H, Dittmann K, Nakata E, Ang K, Milas L. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. IJROBP. 2005;63:520-528. (Pubitemid 41317170)
18. Chung ko J, Han wang L, Yuan jhan J, Ciciou S, Hao hong J, Ting lin S, et al . The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells. Lung Cancer. 2009;65:290-298.
19. Cahlin C, Lönnroth C, Arvidsson A, Nordgren S, Lundholm K. Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol. 2008;32:909-918. (Pubitemid 351780601)
20. Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G. Cox-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001;15:2742-2744.
21. Michaux C, Leval X, Julémont F, Dogné J, Pirotte B, Durant F. Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D data base searching method. Eur J Med Chem. 2006;41:1446- 1455. (Pubitemid 44883393)
22. Bijman M, Hermelink C, Van berkel M, Laan A, Janmaat M, Peters GJ, et al . Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem Pharmacol. 2008;75:427-437. (Pubitemid 350298473)
23. Herrmann M, Lorenz HM, Voll R, Grünke M, Woith W, Kalden JR. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res. 1994;22:5506-5507.
24. Yamanaka Y, Shiraki K, Inoue T, Miyashita K, Fuke H, Yamaguchi Y, et al. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAILinduced apoptosis. Int J Mol Med. 2006;18:41-47.